<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4034731</article-id><article-id pub-id-type="doi">10.1155/2014/364819</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Ligand-Based and Structure-Based Investigation for Alzheimer's Disease from Traditional Chinese Medicine </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Kai Hsin</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Kuen-Bao</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Wen-Yuan</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1465-0330</contrib-id><name><surname>Sun</surname><given-names>Mao-Feng</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Cheng-Chun</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-3306-250X</contrib-id><name><surname>Chen</surname><given-names>Calvin Yu-Chian</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>School of Pharmacy, China Medical University, Taichung 40402, Taiwan</aff><aff id="I2"><sup>2</sup>School of Medicine, College of Medicine, China Medical University, Taichung 40402, Taiwan</aff><aff id="I3"><sup>3</sup>Department of Biomedical Informatics, Asia University, Taichung 41354, Taiwan</aff><author-notes><corresp id="cor1">*Calvin Yu-Chian Chen: <email>ycc929@MIT.edu</email></corresp><fn fn-type="other"><p><text><SENT sid="1" pm="."><plain>Academic Editor: Fuu-Jen Tsai </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>8</day><month>5</month><year>2014</year></pub-date><volume>2014</volume><elocation-id>364819</elocation-id><history><date date-type="received"><day>20</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>12</day><month>1</month><year>2014</year></date></history><permissions><copyright-statement>Copyright © 2014 Kai Hsin Liao et al.</copyright-statement><copyright-year>2014</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Alzheimer's disease is a neurodegenerative disease that was conventionally thought to be related to the sedimentation of beta-amyloids, but drugs designed according to this hypothesis have generally failed. </plain></SENT>
<SENT sid="3" pm="."><plain>That FKBP52 can reduce the accumulation of tau proteins, and that Tacrolimus can reduce the pathological changes of tau proteins are new directions away from the long held amyloid-beta-centric concept. </plain></SENT>
<SENT sid="4" pm="."><plain>Therefore, the screening of traditional Chinese medicine compounds for those with higher affinity towards FKBP52 than Tacrolimus may be a new direction for treating Alzheimer's disease. </plain></SENT>
<SENT sid="5" pm="."><plain>This study utilizes ligand-based and structure-based methods as the foundation. </plain></SENT>
<SENT sid="6" pm="."><plain>By utilizing dock scores and the predicted pIC50 from SVM, MLR, and Bayesian Network, several TCM compounds were selected for further analysis of their protein-ligand interactions. </plain></SENT>
<SENT sid="7" pm="."><plain>Daphnetoxin has higher affinity and complex structure stability than Tacrolimus; Lythrancine II exhibits the most identical trends in FKBP52 interactions as Tacrolimus, and 20-O-(2′E,4′E-decadienoyl)ingenol may be further modified at its hydrocarbon chain to promote interaction with FKBP52. </plain></SENT>
<SENT sid="8" pm="."><plain>In addition, we observed the residue Tyr113 of FKBP52 may play a key role in protein-ligand interaction. </plain></SENT>
<SENT sid="9" pm="."><plain>Our results indicate that Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II may be starting points for further modification as a new type of non-amyloid-beta-centric drug for Alzheimer's disease. </plain></SENT>
</text></SecTag></p></abstract><funding-group><award-group><funding-source>http://dx.doi.org/10.13039/501100001868 National Science Council Taiwan</funding-source><award-id>NSC102-2325-B039-001</award-id></award-group><award-group><funding-source>http://dx.doi.org/10.13039/501100001868 National Science Council Taiwan</funding-source><award-id>NSC102-2221-E-468-027-</award-id></award-group><award-group><funding-source>Asia University</funding-source><award-id>101-ASIA-59</award-id></award-group><award-group><funding-source>Asia University</funding-source><award-id>ASIA100-CMU-2</award-id></award-group><award-group><funding-source>Asia University</funding-source><award-id>ASIA101-CMU-2</award-id></award-group><award-group><funding-source>China Medical University Hospital</funding-source><award-id>DMR-103-058</award-id></award-group><award-group><funding-source>China Medical University Hospital</funding-source><award-id>DMR-103-001</award-id></award-group><award-group><funding-source>China Medical University Hospital</funding-source><award-id>DMR-103-096</award-id></award-group><award-group><funding-source>China Medical University Hospital</funding-source><award-id>CMU102-BC-3</award-id></award-group><award-group><funding-source>Department of Health Clinical Trial and Research Center of Excellence, Taiwan</funding-source><award-id>DOH102-TD-B-111-004</award-id></award-group><award-group><funding-source>Department of Health Cancer Research Center of Excellence, Taiwan</funding-source><award-id>MOHW103-TD-B-111-03</award-id></award-group></funding-group></article-meta></front><body><SecTag type="INTRO"><sec id="sec1"><title><text><SENT sid="10" pm="."><plain>1. </plain></SENT>
<SENT sid="11" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="12" pm="."><plain>Alzheimer's disease (AD) is the most common form of neurodegenerative disease [1–3] with symptoms ranging from intellectual deterioration, cognitive impairment [4, 5] to abnormal behavior, personality changes, depression, and sleep disorders [6, 7]. </plain></SENT>
<SENT sid="13" pm="."><plain>Neuronal loss, senile plaques in the cerebral cortex, and neurofibrillary tangles in the temporal and frontal lobes are prominent in the brains of AD patients. </plain></SENT>
<SENT sid="14" pm="."><plain>Deterioration in the limbic system, including pathological changes in the hippocampus and atrophy of pyramidal cells and the amygdale, has also been reported [8, 9]. </plain></SENT>
<SENT sid="15" pm="."><plain>Formation of β-amyloid plaques [10–13] and neurofibrillary tangles due to abnormal phosphorylation of tau proteins [14] have been linked to AD. </plain></SENT>
</text></p><p><text><SENT sid="16" pm="."><plain>Pioneer research has discovered that the concentration of FKBP52, a FK506-binding protein, is of high density in brain [15] and 40 times higher within the central nervous system than in the immune system [16]. </plain></SENT>
<SENT sid="17" pm="."><plain>FKBP52 is not only related to immune functions but is also important for CNS protective properties. </plain></SENT>
<SENT sid="18" pm="."><plain>Interestingly, they can easily bind with highly phosphorylated tau proteins [16], thereby reducing the accumulation of tau proteins [16–18]. </plain></SENT>
<SENT sid="19" pm="."><plain>FKBP52 was initially discovered as a cochaperone of steroid receptor heterocomplexes [19, 20] and is a member of the FK506-binding protein (FKBP) of immunophilins. </plain></SENT>
<SENT sid="20" pm="."><plain>FKBP52, which possesses a chaperone function, has a PPIase domain also called FK506-binding domain (FKBD), composed of the first 138 amino acids from the N-terminal, exhibits peptidylprolyl isomerase (PPIase) activity, and plays an important role in regulating tau proteins. </plain></SENT>
</text></p><p><text><SENT sid="21" pm="."><plain>Tacrolimus (FK506) is an immunosuppressant typically used to reduce graft rejection during organ transplants [21]. </plain></SENT>
<SENT sid="22" pm="."><plain>Research shows that FK506 can also reduce pathological changes in tau proteins [22] and promote neuroregeneration [23, 24]. </plain></SENT>
<SENT sid="23" pm="."><plain>In addition, FK506 can disrupt steroid receptor heterocomplexes, leading to the release of FKBP52 from the complex and enabling it to function in the nervous system [24–26]. </plain></SENT>
</text></p><p><text><SENT sid="24" pm="."><plain>In recent years, most beta-amyloid-centric drug developments have been unsuccessful during Phase III of clinical trials [27, 28]. </plain></SENT>
<SENT sid="25" pm="."><plain>Currently, the personalized medicine and biomedicine defined an important knowledge for diagnosis and treatment analysis [29, 30], such as rare diseases [31, 32], regional disease [33], signal pathway [34–36], and gene association [37, 38]. </plain></SENT>
<SENT sid="26" pm="."><plain>The traditional Chinese medicine is an important medicine culture in Asia defined as a personalized medicine, system biology, and biomedicine in medicine practices widely applied as treatments for cancer [39, 40], cardiovascular disease [41, 42], diabetes [43], virus disease [44], inflammation [45], and metabolic disorders [46], indicating its large therapeutic potential for various diseases [47]. </plain></SENT>
<SENT sid="27" pm="."><plain>In this moment, the cloud computation and system biology could help the screening for TCM application [48, 49]. </plain></SENT>
<SENT sid="28" pm="."><plain>We have already designed many therapies to different targets [48, 50–57] and have successfully developed method for designing drug in disordered protein [58, 59]. </plain></SENT>
<SENT sid="29" pm="."><plain>The aim of this research is to screen for potential non-amyloid-beta-centric leads from traditional Chinese medicine targeting FKBP52 and to investigate its mechanisms with the hope of providing important insights for forwarding Alzheimer's disease. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="sec2"><title><text><SENT sid="30" pm="."><plain>2. </plain></SENT>
<SENT sid="31" pm="."><plain>Results </plain></SENT>
</text></title><sec id="sec2.1"><title><text><SENT sid="32" pm="."><plain>2.1. </plain></SENT>
<SENT sid="33" pm="."><plain>SVM/MLR/Bayesian Network </plain></SENT>
</text></title><p><text><SENT sid="34" pm="."><plain>The ten representative descriptors determined by GFA were ES_Count_aaCH, ES_Count_sOH, ES_Sum_aaCH, ES_Sum_sssN, Num_Rings6, Molecular_PolarSurfaceArea, CHI_2, Jurs_TPSA, Minimized_Energy, and Shadow_Ylength, suggesting certain relationships between electrotopological properties and polar surface area of ligands with bioactivity (Table S1). </plain></SENT>
</text></p><p><text><SENT sid="35" pm="."><plain>The GFA model with the highest correlation between experimental and predicted pIC50 values (R 2 = 0.9402) was(1)GFATempModel_1 =14.911+80.578×ES_Count_aaCH  −27.224×ES_Count_sOH−44.517×ES_Sum_aaCH  +16.799×ES_Sum_sssN−27.187×Num_Rings6  +0.90601×Molecular_PolarSurfaceArea  −9.6615×CHI_2−0.13155×Jurs_TPSA  −1.1131 Minimized_Energy  +13.232×Shadow_Ylength. Correlation of experimental and predicted pIC50 using the constructed SVM, MLR, and Bayesian Network models is illustrated in Figure 1. R 2 values indicate good prediction accuracy of the constructed models.  Table 1 summarizes bioactivities of the top ten ligands and Tacrolimus predicted by the three constructed models. </plain></SENT>
</text></p></sec><sec id="sec2.2"><title><text><SENT sid="36" pm="."><plain>2.2. </plain></SENT>
<SENT sid="37" pm="."><plain>Docking Analysis </plain></SENT>
</text></title><p><text><SENT sid="38" pm="."><plain>Summary of docking interactions between FKBP52 and the selected ligands is listed in Table 2. </plain></SENT>
<SENT sid="39" pm="."><plain>Tacrolimus interacted with FKBP52 via a single H-bond at Tyr113 and three hydrophobic interactions. </plain></SENT>
<SENT sid="40" pm="."><plain>Higher amounts of total interactions were recorded for TCM candidates. </plain></SENT>
<SENT sid="41" pm="."><plain>With regard to individual residues, interaction percentages suggest the importance of Arg73, Phe77, and Tyr113 for ligand binding. </plain></SENT>
<SENT sid="42" pm="."><plain>Interactions with Arg73 were ligand-dependent, whereas Phe77 and Tyr113 were mutual interaction sites for hydrophobic interactions and H-bonds, respectively. </plain></SENT>
<SENT sid="43" pm="."><plain>Cross comparison reveals that TCM candidates form interactions with all Tacrolimus-interacting residues except Glu85. </plain></SENT>
<SENT sid="44" pm="."><plain>In addition, each TCM candidate is anchored by interactions with residues not recorded for Tacrolimus. </plain></SENT>
<SENT sid="45" pm="."><plain>The higher number of interactions observed for TCM candidates might be associated with higher dock scores and suggests higher binding affinity to FKBP52 than to Tacrolimus.  Figure 2 was demonstrated by Ligplot, showing the hydrophobic interactions and hydrogen bonds between control compound and TCM candidates. </plain></SENT>
<SENT sid="46" pm="."><plain>Except for the H-bond between residue Tyr57 and Daphnetoxin, the results were the same for docking analysis. </plain></SENT>
</text></p></sec><sec id="sec2.3"><title><text><SENT sid="47" pm="."><plain>2.3. </plain></SENT>
<SENT sid="48" pm="."><plain>Candidate Selection </plain></SENT>
</text></title><p><text><SENT sid="49" pm="."><plain>Docking scores, predicted bioactivities, and corresponding consensus scores are detailed in Table 1, respectively. </plain></SENT>
<SENT sid="50" pm="."><plain>In general, candidates with higher dock scores than Tacrolimus were also predicted to have similar if not better bioactivities. </plain></SENT>
<SENT sid="51" pm="."><plain>Daphnetoxin (TCM origin: Daphne giraldii Nitsche), 20-O-(2′E,4′E-decadienoyl)ingenol (TCM origin: Euphorbia kansui), and Lythrancine II (TCM origin: Lythrum salicaria) were selected as research candidates based on the consensus voting system (Table 1). </plain></SENT>
<SENT sid="52" pm="."><plain>Structural scaffolds of Tacrolimus and the selected candidates are illustrated in Figure 3. </plain></SENT>
</text></p></sec><sec id="sec2.4"><title><text><SENT sid="53" pm="."><plain>2.4. </plain></SENT>
<SENT sid="54" pm="."><plain>Molecular Dynamics Simulation </plain></SENT>
</text></title><sec id="sec2.4.1"><title><text><SENT sid="55" pm="."><plain>2.4.1. </plain></SENT>
<SENT sid="56" pm="."><plain>Stability Profile Analysis </plain></SENT>
</text></title><p><text><SENT sid="57" pm="."><plain>Figure 4 illustrates protein-ligand complex stability in terms of RMSD and total energy. </plain></SENT>
<SENT sid="58" pm="."><plain>In general, the complex RMSD of Daphnetoxin and 20-O-(2′E,4′E-decadienoyl)ingenol was higher (1.5 Å´–5.5 Å´) and showed larger fluctuation than that of Tacrolimus and Lythrancine II. </plain></SENT>
<SENT sid="59" pm="."><plain>RMSD trajectories of FKBP52 complexed with Tacrolimus or Lythrancine II were similar, ranging between 1.5 Å´ and 4 Å´. </plain></SENT>
<SENT sid="60" pm="."><plain>With the exception of 20-O-(2′E,4′E-decadienoyl)ingenol, ligands reached dynamic equilibrium with small fluctuations during MD simulation. </plain></SENT>
<SENT sid="61" pm="."><plain>Notwithstanding differences in complex or ligand RMSD, all complexes exhibited stable complex energy trajectories between −1,010,000 kJ/mol and −1,004,000 kJ/mol during MD. </plain></SENT>
</text></p></sec></sec><sec id="sec2.5"><title><text><SENT sid="62" pm="."><plain>2.5. </plain></SENT>
<SENT sid="63" pm="."><plain>RMS Fluctuation (RMSF) of Protein Residues </plain></SENT>
</text></title><p><text><SENT sid="64" pm="."><plain>Residues contributing to complex structural fluctuations can be assessed by root mean square fluctuations (RMSFs) of each residue (Figure 5). </plain></SENT>
<SENT sid="65" pm="."><plain>Tacrolimus and Lythrancine II have lower RMSFs and similar trends. </plain></SENT>
<SENT sid="66" pm="."><plain>20-O-(2′E,4′E-Decadienoyl)ingenol has the highest RMSF of the four, implying greater fluctuations. </plain></SENT>
<SENT sid="67" pm="."><plain>Daphnetoxin falls between Tacrolimus, Lythrancine II, and 20-O-(2′E,4′E-decadienoyl)ingenol. </plain></SENT>
<SENT sid="68" pm="."><plain>Analysis of the RMSF values shows that great differences among the protein complexes were observed at Tyr113, a residue near the binding site. </plain></SENT>
</text></p></sec><sec id="sec2.6"><title><text><SENT sid="69" pm="."><plain>2.6. </plain></SENT>
<SENT sid="70" pm="."><plain>H-Bond Network during MD Simulation </plain></SENT>
</text></title><p><text><SENT sid="71" pm="."><plain>Next we investigated formation and stability of H-bonds under dynamic conditions. </plain></SENT>
<SENT sid="72" pm="."><plain>Individual occupancies of detected H-bonds per ligand are detailed in Table S2. </plain></SENT>
<SENT sid="73" pm="."><plain>H-bond trajectories depicting time-dependent bond distance variations are illustrated in Figure 6. </plain></SENT>
<SENT sid="74" pm="."><plain>Since optimum H-bonds are formed between 2.3 and 3.2 Å and most bond distances formed between Tacrolimus and FKBP52 residues exceed this distance, we conclude that, during MD, the protein-ligand complex stability was maintained by interactions with Glu110 and Ala 112. </plain></SENT>
</text></p><p><text><SENT sid="75" pm="."><plain>Daphnetoxin forms several discontinuous H-bonds with residues of FKBP52. </plain></SENT>
<SENT sid="76" pm="."><plain>However, the H-bond occupancies at Tyr113 with O16, O18, and H52 of Daphnetoxin are 31.47%, 2.00%, and 9.89%, respectively. </plain></SENT>
<SENT sid="77" pm="."><plain>It suggests that the Tyr113 might play an important role in protein-ligand complex stability. </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>20-O-(2′E,4′E-Decadienoyl)ingenol and the residues of FKBP52 form some unstable H-bonds. </plain></SENT>
<SENT sid="79" pm="."><plain>Tyr113, O21 and H60 form only transient H-bonds during MD, whereas Asp68 and Lys121 form a stable H-bond with 20-O-(2′E,4′E-decadienoyl)ingenol from 13 to 20 ns. </plain></SENT>
</text></p><p><text><SENT sid="80" pm="."><plain>Lythrancine II and residues of FKBP52 form two stable H-bonds: Ile87 forms a stable H-bond at O36 from 6 to 17.5 ns. </plain></SENT>
<SENT sid="81" pm="."><plain>Tyr113 and O19 on Lythrancine II form a stable H-bond from 0 to 17.5 ns. </plain></SENT>
<SENT sid="82" pm="."><plain>The two residues are important for protein-ligand complex stability. </plain></SENT>
</text></p></sec><sec id="sec2.7"><title><text><SENT sid="83" pm="."><plain>2.7. </plain></SENT>
<SENT sid="84" pm="."><plain>Torsion MD Simulation </plain></SENT>
</text></title><p><text><SENT sid="85" pm="."><plain>Analysis of torsion helps us understand the stability of ligand and protein binding (Figure 7, Figure S1; see Supplementary Material available online at <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1155/2014/364819">http://dx.doi.org/10.1155/2014/364819</ext-link>). </plain></SENT>
<SENT sid="86" pm="."><plain>Torsion (A1) of Tacrolimus changes from significant unstable rotations (0–7.5 ns) to stable rotations (7.5–17 ns), and change to unstable rotations after 17 ns. </plain></SENT>
<SENT sid="87" pm="."><plain>Comparing to H-bond simulation results, we can assume that Glu110 forms a more stable H-bond. </plain></SENT>
<SENT sid="88" pm="."><plain>Torsion (A4) is more stable from 2 to 6 ns. </plain></SENT>
<SENT sid="89" pm="."><plain>During this period, H-bond simulation shows the formation of an H-bond between FKBP52 and Ser118. </plain></SENT>
<SENT sid="90" pm="."><plain>Torsion (A5) shows some changes, but the small torsion fluctuations at (A2), (A3), (A6), and (A7) show that they have higher stability. </plain></SENT>
<SENT sid="91" pm="."><plain>Torsion (B8) of Daphnetoxin shows transient stability. </plain></SENT>
<SENT sid="92" pm="."><plain>Torsion (B9) is stable with small fluctuations. </plain></SENT>
<SENT sid="93" pm="."><plain>Torsion (B10) has smaller torsion fluctuations from 0 to 10 ns; torsion (B11) also has very small changes. </plain></SENT>
<SENT sid="94" pm="."><plain>During this period, they separately form H-bonds with Glu85 and Ile87 on FKBP52. </plain></SENT>
<SENT sid="95" pm="."><plain>Torsion (B12) has small fluctuations from 8 to 18 ns, and torsion (B13) is relatively stable; these locations form H-bonds with Tyr57 and Tyr113. </plain></SENT>
<SENT sid="96" pm="."><plain>Violent fluctuations at (C14) were observed for 20-O-(2′E,4′E-decadienoyl)ingenol, a phenomenon probably due to the lack of stabilizing bonds with FKBP52. </plain></SENT>
<SENT sid="97" pm="."><plain>Torsions (C15) and (C16) only form short lived H-bonds which could be attributed to the large torsion changes. </plain></SENT>
<SENT sid="98" pm="."><plain>Torsion (C17) is relatively stable. </plain></SENT>
<SENT sid="99" pm="."><plain>With the exception of isolated large fluctuations, torsion (D18) is relatively stable, probably due to the formation of H-bond with Ser118. </plain></SENT>
<SENT sid="100" pm="."><plain>Torsion (D19) is relatively stable up until 12.5 ns when increased fluctuation was observed. </plain></SENT>
<SENT sid="101" pm="."><plain>Torsion (D20) is stable, most likely due to the H-bonds formed between Lythrancine II and Tyr57 and Asp68. </plain></SENT>
<SENT sid="102" pm="."><plain>Torsions (D21) and (D22) had large fluctuations. </plain></SENT>
</text></p></sec><sec id="sec2.8"><title><text><SENT sid="103" pm="."><plain>2.8. </plain></SENT>
<SENT sid="104" pm="."><plain>DSSP MD Simulation </plain></SENT>
</text></title><p><text><SENT sid="105" pm="."><plain>Protein functionality is affected by the tertiary structure formed by the secondary structures. </plain></SENT>
<SENT sid="106" pm="."><plain>The conformation changes of protein secondary structures for each time frame can be computed by the DSSP program. </plain></SENT>
<SENT sid="107" pm="."><plain>Changes in the secondary protein structure when Tacrolimus, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, or Lythrancine II is bound to FKBP52 are illustrated in Figure 8. </plain></SENT>
<SENT sid="108" pm="."><plain>Tacrolimus, Daphnetoxin, and Lythrancine II have an α-helix composition of approximately 6%, but that of 20-O-(2′E,4′E-decadienoyl)ingenol ranges between 6 and 10%. </plain></SENT>
<SENT sid="109" pm="."><plain>Compositions of β-sheets and turns in the four complexes are approximately 38-39% and 15–20%, but an increase in turn structures was observed in 20-O-(2′E,4′E-decadienoyl)ingenol from 12 ns. </plain></SENT>
<SENT sid="110" pm="."><plain>From Figure 8 we can observe more significant changes at residue 51. </plain></SENT>
<SENT sid="111" pm="."><plain>In Tacrolimus, residue 51 is a bend, but in Daphnetoxin, it turns into a turn at 0-1 ns and 12–18 ns. </plain></SENT>
<SENT sid="112" pm="."><plain>Similarly in 20-O-(2′E,4′E-decadienoyl)ingenol, the residue becomes a turn after 1 ns and after 11 ns. </plain></SENT>
<SENT sid="113" pm="."><plain>In Lythrancine II, it first appears as a turn from 0 to 2 ns, then turns to bend, and then fluctuates between bends and turns. </plain></SENT>
<SENT sid="114" pm="."><plain>Comparisons to RMSFs show that RMSF of residue 51 is also larger. </plain></SENT>
</text></p></sec><sec id="sec2.9"><title><text><SENT sid="115" pm="."><plain>2.9. </plain></SENT>
<SENT sid="116" pm="."><plain>Solvent Accessible Surface Area (SASA) in MD Simulation </plain></SENT>
</text></title><p><text><SENT sid="117" pm="."><plain>Solvent accessible surface area (SASA) analysis measures the interaction between complexes and solvents. </plain></SENT>
<SENT sid="118" pm="."><plain>SASAs of the ligand-protein complexes are 140.788 nm/NS2, 141.028 nm/NS2, 141.745 nm/NS2, and 140.004 nm/NS2 for Tacrolimus, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II, respectively. </plain></SENT>
<SENT sid="119" pm="."><plain>Average of the ligand SASAs is 9.068 nm/NS2, 5.669 nm/NS2, 6.827 nm/NS2, and 5.978 nm/NS2, respectively. </plain></SENT>
<SENT sid="120" pm="."><plain>According to the results of proteins and ligands, both the values of 20-O-(2′E,4′E-decadienoyl)ingenol are the greatest, suggesting that it should be accessible for solvents and have more interaction with solvents. </plain></SENT>
<SENT sid="121" pm="."><plain>In addition, we observed that the SASA values for the four protein complexes (Figure 9(a)) and the ligands (Figure 9(b)) during MD is relatively stable, indicating no significant changes in the protein structure. </plain></SENT>
</text></p></sec><sec id="sec2.10"><title><text><SENT sid="122" pm="."><plain>2.10. </plain></SENT>
<SENT sid="123" pm="."><plain>Radius of Gyration (Rg) in MD Simulation </plain></SENT>
</text></title><p><text><SENT sid="124" pm="."><plain>Radius of gyration (Rg) enables one to assess the compactness changes of a ligand-protein complex. </plain></SENT>
<SENT sid="125" pm="."><plain>Average and maximum values for Tacrolimus, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II are listed in Table 3. </plain></SENT>
<SENT sid="126" pm="."><plain>No significant changes were observed for Rgcomplex (Figure 9(c)) and Rgligand (Figure 9(d)), implying a sustained stability and compactness of the complexes. </plain></SENT>
<SENT sid="127" pm="."><plain>However, fluctuations in Rgcomplex and Rgligand were recorded for 20-O-(2′E,4′E-decadienoyl)ingenol, suggesting a loss of compactness for its complex. </plain></SENT>
<SENT sid="128" pm="."><plain>Comparing to H-bond simulation results in Figure 6, the Rgcomplex of Tacrolimus presents maxima at 7 ns, and Gly84, Tyr113, and Ser118 trajectories also have the same trade in Figure 6(a). </plain></SENT>
<SENT sid="129" pm="."><plain>The Rgcomplex of Daphnetoxin presents maxima at 3.5 ns, and Tyr113 with H52 at 3.5 ns also presents maxima. </plain></SENT>
<SENT sid="130" pm="."><plain>Moreover, the Rgcomplex at 6 ns and 11 to 14 ns have higher values, and they correspond to Ile87, Glu85, and Tyr113 trajectories in Figure 6(b). </plain></SENT>
<SENT sid="131" pm="."><plain>The minima of Rgcomplex at 6.5 ns in 20-O-(2′E,4′E-decadienoyl)ingenol, similar to that of Tyr113, Lys121 trajectories (Figure 6(c)). </plain></SENT>
<SENT sid="132" pm="."><plain>In addition, the Rgcomplex presents maxima at 9 ns, and Tyr113 trajectory matches it. </plain></SENT>
<SENT sid="133" pm="."><plain>The Rgcomplex of Lythrancine II presents two maxima at 11 ns and 15 ns, corresponding to Asp68 and Ser118 trajectories and Tyr113 trajectory, respectively (Figure 6(d)). </plain></SENT>
<SENT sid="134" pm="."><plain>In conclusion, when Rgcomplex is higher, the compactness of ligand-protein complex is lower causing the interactions between ligand and protein to be more weak. </plain></SENT>
</text></p></sec><sec id="sec2.11"><title><text><SENT sid="135" pm="."><plain>2.11. </plain></SENT>
<SENT sid="136" pm="."><plain>Cluster MD Simulation </plain></SENT>
</text></title><p><text><SENT sid="137" pm="."><plain>MD simulations from 15 to 20 ns were used for cluster analysis (Figure 10 and Figure S2) to find the conformation with the highest frequency during the end of MD. </plain></SENT>
<SENT sid="138" pm="."><plain>According to our analysis results, the representative conformation for each protein-ligand complex was represented by the conformations at 19.02 ns for Tacrolimus, 19.32 ns for Daphnetoxin, 19.58 ns for 20-O-(2′E,4′E-decadienoyl)ingenol, and 19.72 ns for Lythrancine II. </plain></SENT>
</text></p><p><text><SENT sid="139" pm="."><plain>Comparing the conformation at 0 ns and the representative conformation for each complex is shown in Figure 11. </plain></SENT>
<SENT sid="140" pm="."><plain>Tacrolimus initially form an H-bond with Tyr113, but this H-bond is lost following stabilization. </plain></SENT>
<SENT sid="141" pm="."><plain>Moreover, the movement of Tacrolimus into the interior of the protein complex (Figure 11(a)) and the higher ligand RMSD (Figure 4) were observed. </plain></SENT>
<SENT sid="142" pm="."><plain>Therefore, the significant change of Tacrolimus might cause the H-bond to disappear and impact the interaction between Tacrolimus and FKBP52 deeply. </plain></SENT>
<SENT sid="143" pm="."><plain>The complex RMSD of Daphnetoxin is higher, but the ligand RMSD reach dynamic equilibrium with small fluctuations (Figure 4), it might cause Daphnetoxin to form two H-bonds with Tyr113, and this was maintained throughout MD (Figure 11(b)). </plain></SENT>
<SENT sid="144" pm="."><plain>The conformation of 20-O-(2′E,4′E-decadienoyl)ingenol and protein shows great differences between 0 ns and 19.58 ns at MD simulation. </plain></SENT>
<SENT sid="145" pm="."><plain>Especially, the position and the side chain of ligand have obvious changes. </plain></SENT>
<SENT sid="146" pm="."><plain>Comparing to Figure 4, its complex RMSD and ligand RMSD are higher and show larger fluctuation. </plain></SENT>
<SENT sid="147" pm="."><plain>As a result, 20-O-(2′E,4′E-decadienoyl)ingenol forms H-bonds with Tyr113 and Lys121 at the beginning of MD, but only the bond with Lys121 was maintained following stabilization (Figure 11(c)). </plain></SENT>
<SENT sid="148" pm="."><plain>Lythrancine II forms H-bonds with Asp68, Arg73, and Tyr113 at the beginning of MD, but these bonds are lost after stabilization, even though its complex RMSD and ligand RMSD are not higher. </plain></SENT>
<SENT sid="149" pm="."><plain>It might be attributed to the huge conformation change of the ligand. </plain></SENT>
<SENT sid="150" pm="."><plain>Similar to Tacrolimus, Lythrancine II was observed to be more embedded in the interior of the protein complex (Figure 11(d)). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec id="sec3"><title><text><SENT sid="151" pm="."><plain>3. </plain></SENT>
<SENT sid="152" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="153" pm="."><plain>Discrepancies between docking and MD simulation results were observed. </plain></SENT>
<SENT sid="154" pm="."><plain>During docking, Tacrolimus, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II were predicted to form H-bonds with Tyr113 of FKBP52. </plain></SENT>
<SENT sid="155" pm="."><plain>Nonetheless, occupancies of the H-bond with Tyr113 varied greatly. </plain></SENT>
<SENT sid="156" pm="."><plain>Similarly, RMSF also shows that Tyr113 has great differences among the four complexes. </plain></SENT>
<SENT sid="157" pm="."><plain>In Table S2, we can see that the occupancies of Tyr113 in the Tacrolimus complex are only 0.3% and 1.6%. </plain></SENT>
<SENT sid="158" pm="."><plain>The occupancies of Tyr113 in the Daphnetoxin complex are 31.47% and 2.00%; therefore the H-bond can still be observed when stabilized. </plain></SENT>
<SENT sid="159" pm="."><plain>The occupancies of Tyr113 in the 20-O-(2′E,4′E-decadienoyl)ingenol complex are only 1.8% and 0.6%. </plain></SENT>
<SENT sid="160" pm="."><plain>But the bonds with Lys121 were observed during docking and were maintained during MD simulation with occupancies of 9.09% and 8.99%. </plain></SENT>
<SENT sid="161" pm="."><plain>The occupancies of Tyr113 with Lythrancine II complex are 9.29% and 3.5%, but H-bonds were not observed in the stabilized complex. </plain></SENT>
</text></p><p><text><SENT sid="162" pm="."><plain>From other MD simulation analysis we can make the following summarizations. </plain></SENT>
<SENT sid="163" pm="."><plain>Despite the larger protein complex RMSD of Daphnetoxin compared to Tacrolimus, the H-bond with Tyr113 was presented during both docking and MD simulation, indicating a better affinity towards FKBP52 than Tacrolimus. </plain></SENT>
<SENT sid="164" pm="."><plain>Summarizing the results from RMSF, SASA, and Rg, the protein complex of Daphnetoxin is stable during MD simulation. </plain></SENT>
<SENT sid="165" pm="."><plain>20-O-(2′E,4′E-Decadienoyl)ingenol has higher complex and ligand RMSDs than Tacrolimus and also has more prominent changes in secondary structure changes, RMSF, and Rg. </plain></SENT>
<SENT sid="166" pm="."><plain>This could be related to the hydrophobic hydrocarbon backbone in its structure. </plain></SENT>
<SENT sid="167" pm="."><plain>However, 20-O-(2′E,4′E-decadienoyl)ingenol forms more hydrophobic interactions than Tacrolimus and is able to maintain the H-bond with Lys121 following stabilization, suggesting affinity with FKBP52. </plain></SENT>
<SENT sid="168" pm="."><plain>In addition, 20-O-(2′E,4′E-decadienoyl)ingenol has maximum values of SASA analysis of proteins and ligands, indicating that it should be accessible for solvents and have more interaction with solvents. </plain></SENT>
<SENT sid="169" pm="."><plain>Though Lythrancine II do not have H-bonds in the stabilized MD simulation conformation, its complex RMSD, ligand RMSD, RMSF, and Rg trends are most similar to Tacrolimus. </plain></SENT>
<SENT sid="170" pm="."><plain>In addition, movement of Lythrancine II towards the protein interior is also reminiscent of Tacrolimus. </plain></SENT>
<SENT sid="171" pm="."><plain>Therefore, Lythrancine II shows the most similar ligand-protein conformation with Tacrolimus. </plain></SENT>
<SENT sid="172" pm="."><plain>From this study, we can also see the importance of MD simulation in computer-aided drug designs. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec id="sec4"><title><text><SENT sid="173" pm="."><plain>4. </plain></SENT>
<SENT sid="174" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="175" pm="."><plain>We aimed to utilize structure-based and ligand-based methods to screen for high affinity lead compounds for FKBP52 as alternatives for Tacrolimus to develop better non-amyloid-beta-centric therapies for Alzheimer's disease. </plain></SENT>
<SENT sid="176" pm="."><plain>Utilizing docking and highly reliable QSAR models, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II were selected as potential candidates. </plain></SENT>
<SENT sid="177" pm="."><plain>Docking, Ligplot, and MD show that Daphnetoxin and Lythrancine II both have better affinity to FKBP52 than Tacrolimus. </plain></SENT>
<SENT sid="178" pm="."><plain>For 20-O-(2′E,4′E-decadienoyl)ingenol, modifying its long chain hydrocarbon could improve interaction with FKBP52. </plain></SENT>
<SENT sid="179" pm="."><plain>Based on these results, there is possibility to utilize Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II as backbone structures for modification as a new approach for designing Alzheimer's disease. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec id="sec5"><title><text><SENT sid="180" pm="."><plain>5. </plain></SENT>
<SENT sid="181" pm="."><plain>Material and Methods </plain></SENT>
</text></title><sec id="sec5.1"><title><text><SENT sid="182" pm="."><plain>5.1. </plain></SENT>
<SENT sid="183" pm="."><plain>Data Collection </plain></SENT>
</text></title><p><text><SENT sid="184" pm="."><plain>The FKBP52 crystal structure (PDB ID: 1Q1C) was downloaded from Protein Data Bank [60] and corrected for H-atoms using the Prepare Ligands module in Discovery Studio Client v2.5 (DS2.5; Accelrys Inc., San Diego, CA). </plain></SENT>
<SENT sid="185" pm="."><plain>Ligand structures and activity data from Gopalakrishnan's study [61] were used to construct quantitative structure-activity relationship (QSAR) prediction models for FKBP52. </plain></SENT>
<SENT sid="186" pm="."><plain>TCM ligands used for virtual screening were downloaded from TCM Database@Taiwan [62]. </plain></SENT>
<SENT sid="187" pm="."><plain>Tacrolimus (FK506), the clinically used immunosuppressant, was used as the control. </plain></SENT>
</text></p></sec><sec id="sec5.2"><title><text><SENT sid="188" pm="."><plain>5.2. </plain></SENT>
<SENT sid="189" pm="."><plain>Molecular Docking </plain></SENT>
</text></title><p><text><SENT sid="190" pm="."><plain>Prior to virtual screening, Change Ionization in the Prepare Ligands module (DS 2.5) was applied to adjust ionization states of the downloaded ligands. </plain></SENT>
<SENT sid="191" pm="."><plain>Downloaded ligands and Tacrolimus were docked to the PPIase domain of FKBP52 under a forcefield of Chemistry at HARvard Molecular Mechanics (CHARMm) using the LigandFit module. </plain></SENT>
<SENT sid="192" pm="."><plain>Ligands were evaluated based on structural compatibility to the PPIase domain and dock score was selected as the scoring function. </plain></SENT>
</text></p></sec><sec id="sec5.3"><title><text><SENT sid="193" pm="."><plain>5.3. </plain></SENT>
<SENT sid="194" pm="."><plain>Support Vector Machine (SVM) and Multiple Linear Regression (MLR) Prediction Models </plain></SENT>
</text></title><p><text><SENT sid="195" pm="."><plain>The 37 ligands [61] were randomly divided into a training set of 30 compounds and a test set of 7 compounds. </plain></SENT>
<SENT sid="196" pm="."><plain>Molecular properties of each ligand were calculated with Calculate Molecular Properties and the ten representative descriptors most related to bioactivity were determined by Genetic Function Approximation (GFA). </plain></SENT>
<SENT sid="197" pm="."><plain>Different prediction models were constructed with the representative descriptors and the strength of each model ranked by a square correlation coefficient (R 2). </plain></SENT>
<SENT sid="198" pm="."><plain>Descriptors in the highest R 2 model were used to construct a nonlinear SVM model with LibSVM and a linear MLR model with MATLAB. </plain></SENT>
<SENT sid="199" pm="."><plain>The constructed models were validated with the test sets and applied to predict bioactivity of selected TCM candidates. </plain></SENT>
</text></p></sec><sec id="sec5.4"><title><text><SENT sid="200" pm="."><plain>5.4. </plain></SENT>
<SENT sid="201" pm="."><plain>Bayesian Network </plain></SENT>
</text></title><p><text><SENT sid="202" pm="."><plain>Training/test set groups and representative descriptors determined by GFA were also used to construct the Bayesian Network model. </plain></SENT>
<SENT sid="203" pm="."><plain>According to distribution characteristics, descriptors and pIC50 were discretized into a maximum of five categories. </plain></SENT>
<SENT sid="204" pm="."><plain>Linear regression analysis for each pIC50 category in the training dataset was then applied. </plain></SENT>
<SENT sid="205" pm="."><plain>Banjo [63] was used to discover relationships among the representative descriptors and pIC50 values. </plain></SENT>
<SENT sid="206" pm="."><plain>The algorithm for predicting pIC50 was written in MATLAB codes integrating Banjo and Bayes Net Toolbox (BNT; <ext-link ext-link-type="uri" xlink:href="https://code.google.com/p/bnt/">https://code.google.com/p/bnt/</ext-link>). </plain></SENT>
<SENT sid="207" pm="."><plain>Following validation, the algorithm was applied to predict bioactivity of selected TCM candidates. </plain></SENT>
</text></p></sec><sec id="sec5.5"><title><text><SENT sid="208" pm="."><plain>5.5. </plain></SENT>
<SENT sid="209" pm="."><plain>Candidate Selection Criteria </plain></SENT>
</text></title><p><text><SENT sid="210" pm="."><plain>All TCM ligands with dock scores lower than Tacrolimus were eliminated. </plain></SENT>
<SENT sid="211" pm="."><plain>Next, a consensus voting system was used for candidate selection. </plain></SENT>
<SENT sid="212" pm="."><plain>The three highest scoring candidates in dock score, SVM, or MLR were given a score of “1”; candidates with the three highest Bayesian Network scores were given a score of “2.” Sum of scores was calculated and the three ligands with the highest scores were selected as candidates for further analysis. </plain></SENT>
</text></p></sec><sec id="sec5.6"><title><text><SENT sid="213" pm="."><plain>5.6. </plain></SENT>
<SENT sid="214" pm="."><plain>Molecular Dynamics (MD) Simulation </plain></SENT>
</text></title><p><text><SENT sid="215" pm="."><plain>Candidates and Tacrolimus were prepared with SwissParam (<ext-link ext-link-type="uri" xlink:href="http://swissparam.ch/">http://swissparam.ch/</ext-link>) [64] prior to MD. </plain></SENT>
<SENT sid="216" pm="."><plain>MD simulation was conducted with GROMACS 4.0.7 under the forcefield of CHARMm27. </plain></SENT>
<SENT sid="217" pm="."><plain>Distance of protein to box boundaries was 1.2 nm; solvate TIP3P water model was then added to the system. </plain></SENT>
<SENT sid="218" pm="."><plain>Complex charges were neutralized with sodium and chloride ions using 0.145 M salt model. </plain></SENT>
<SENT sid="219" pm="."><plain>Simulation was conducted at 310 K under a pressure of 1 bar. </plain></SENT>
<SENT sid="220" pm="."><plain>Each complex was minimized with 5,000 steps of Steepest Descent, and the final minimized structure was used as the initial structure for MD simulation. </plain></SENT>
<SENT sid="221" pm="."><plain>Electrostatic interactions were calculated with Particle-Mesh-Ewald (PME) [65]. </plain></SENT>
<SENT sid="222" pm="."><plain>Equilibration protocol was used to restrain and relax protein-ligand position; first-order kinetics was started from 300 K. Minimized system was used to simulate a five-thousand ps configuration production. </plain></SENT>
<SENT sid="224" pm="."><plain>MD simulation was conducted for 20 ns with time steps of 2 fs under PME. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="supplementary-material-sec"><title><text><SENT sid="225" pm="."><plain>Supplementary Material </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="f1"><caption><p><text><SENT sid="226" pm="."><plain>Table S1. </plain></SENT>
<SENT sid="227" pm="."><plain>Descriptions of representative descriptors associated with bioactivity determined by GFA. </plain></SENT>
</text></p><p><text><SENT sid="228" pm="."><plain>Table S2. </plain></SENT>
<SENT sid="229" pm="."><plain>H-bond interactions of FKBP52 with TCM candidates and Tacrolimus in MD simulation. </plain></SENT>
</text></p><p><text><SENT sid="230" pm="."><plain>Figure S1. </plain></SENT>
<SENT sid="231" pm="."><plain>Details about torsion angles of control and TCM candidates in FKBP52 complex. </plain></SENT>
<SENT sid="232" pm="."><plain>(A) Tacrolimus, (B) Daphnetoxin, (C) 20-O-(2´E,4´E-decadienoyl)ingenol, and (D) Lythrancine II. </plain></SENT>
<SENT sid="233" pm="."><plain>(gray(X):original torsion anglesred(Y): if X&lt;0,Y=X+360, blue(Z)=Y(i+1)-Y) </plain></SENT>
</text></p><p><text><SENT sid="234" pm="."><plain>Figure S2. </plain></SENT>
<SENT sid="235" pm="."><plain>Distance matrices depicting the smallest distance between residue pairs. </plain></SENT>
<SENT sid="236" pm="."><plain>(A) Tacrolimus, (B) Daphnetoxin, (C) 20-O-(2´E,4´E-decadienoyl)ingenol, and (D) Lythrancine II. </plain></SENT>
</text></p></caption><media xlink:href="364819.f1.docx"><caption><p><text><SENT sid="237" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="238" pm="."><plain>The research was supported by Grants from the National Science Council of Taiwan (NSC102-2325-B039-001 and NSC102-2221-E-468-027-), Asia University (101-ASIA-59, ASIA100-CMU-2, and ASIA101-CMU-2), and China Medical University Hospital (DMR-103-058, DMR-103-001, and DMR-103-096, CMU102-BC-3). </plain></SENT>
<SENT sid="239" pm="."><plain>This study is also supported in part by Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) and Taiwan Department of Health Cancer Research Center of Excellence (MOHW103-TD-B-111-03). </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="COMP_INT"><sec sec-type="conflict"><title>Conflict of Interests</title><p>The authors declare that there is no conflict of interests regarding the publication of this paper.</p></sec></SecTag><SecTag type="AUTH_CONT"><sec><title>Authors' Contribution</title><p>Kai Hsin Liao, Kuen-Bao Chen, and Wen-Yuan Lee contributed equally to this work.</p></sec></SecTag><SecTag type="REF"><ref-list><ref id="B1"><text><SENT sid="240" pm="."><plain>1AdamsRLCraigPLParsonsOANeuropsychology of dementiaNeurologic Clinics1986423874042-s2.0-00229221332940456 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="241" pm="."><plain>2CummingsJLSubcortical dementia. </plain></SENT>
<SENT sid="242" pm="."><plain>Neuropsychology, neuropsychiatry, and pathophysiologyBritish Journal of Psychiatry19861496826972-s2.0-00230005562878699 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="243" pm="."><plain>3SavlaGNPalmerBWNeuropsychology in Alzheimer’s disease and other dementia researchCurrent Opinion in Psychiatry20051866216272-s2.0-2764454765816639085 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="244" pm="."><plain>4JostBCGrossbergGTThe evolution of psychiatric symptoms in Alzheimer’s disease: a natural history studyJournal of the American Geriatrics Society1996449107810812-s2.0-00298152998790235 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="245" pm="."><plain>5SelkoeDJAlzheimer’s disease is a synaptic failureScience200229855947897912-s2.0-003717461812399581 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="246" pm="."><plain>6HarwoodDGBarkerWWOwnbyRLDuaraRRelationship of behavioral and psychological symptoms to cognitive impairment and functional status in Alzheimer's diseaseInternational Journal of Geriatric Psychiatry200015539340010822237 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="247" pm="."><plain>7HauptMKurzAJännerMA 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s diseaseDementia and Geriatric Cognitive Disorders20001131471522-s2.0-003399436910765045 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="248" pm="."><plain>8HooperMWVogelFSThe limbic system in Alzheimer’s disease. </plain></SENT>
<SENT sid="249" pm="."><plain>A neuropathologic investigationThe American Journal of Pathology19768511202-s2.0-0017139133135514 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="250" pm="."><plain>9MiletichRSChaseTNBlesaRLimbic system dysfunction in Alzheimer’s diseaseJournal of Neurology Neurosurgery and Psychiatry19955944504512-s2.0-0029148218 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="251" pm="."><plain>10HarrisJADevidzeNVerretLTranssynaptic progression of Amyloid-β-induced neuronal dysfunction within the entorhinal-hippocampal networkNeuron20106834284412-s2.0-7804928375621040845 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="252" pm="."><plain>11ZempelHMandelkowE-MLinking amyloid-β and tau: amyloid-β induced synaptic dysfunction via local wreckage of the neuronal cytoskeletonNeurodegenerative Diseases2012101–464722-s2.0-8486021405522156588 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="253" pm="."><plain>12NimmrichVEbertUIs alzheimer’s disease a result of presynaptic failure?—Synaptic dysfunctions induced by oligomeric p-amyloidReviews in the Neurosciences20092011122-s2.0-6704915950519526730 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="254" pm="."><plain>13BuscheMAChenXHenningHACritical role of soluble amyloid-beta for early hippocampal hyperactivity in a mouse model of Alzheimer's diseaseProceedings of the National Academy of Sciences of the United States of America2012109228740874522592800 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="255" pm="."><plain>14MaccioniRBMuñozJPBarbeitoLThe molecular bases of Alzheimer’s disease and other neurodegenerative disordersArchives of Medical Research20013253673812-s2.0-003482980111578751 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="256" pm="."><plain>15SteinerJPDawsonTMFotuhiMHigh brain densities of the immunophilin FKBP colocalized with calcineurinNature199235863875845872-s2.0-00266737721380130 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="257" pm="."><plain>16GiustinianiJSineusMSardinEDecrease of the immunophilin FKBP52 accumulation in human brains of alzheimer’s disease and FTDP-17Journal of Alzheimer’s Disease20122924714832-s2.0-84859392758 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="258" pm="."><plain>17ChambraudBSardinEGiustinianiJA role for FKBP52 in Tau protein functionProceedings of the National Academy of Sciences of the United States of America20101076265826632-s2.0-7724917754720133804 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="259" pm="."><plain>18CaoWKonsolakiMFKBP immunophilins and Alzheimer’s disease: a chaperoned affairJournal of Biosciences20113634934982-s2.0-8005482882921799260 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="260" pm="."><plain>19KangCBHongYDhe-PaganonSYoonHSFKBP family proteins: immunophilins with versatile biological functionsNeuroSignals20081643183252-s2.0-5714909320318635947 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="261" pm="."><plain>20PrattWBToftDOSteroid receptor interactions with heat shock protein and immunophilin chaperonesEndocrine Reviews19971833063602-s2.0-00309256839183567 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="262" pm="."><plain>21SchreiberSLChemistry and biology of the immunophilins and their immunosuppressive ligandsScience199125149912832872-s2.0-00260305681702904 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="263" pm="."><plain>22YoshiyamaYHiguchiMZhangBSynapse loss and microglial activation precede tangles in a P301S tauopathy mouse modelNeuron20075333373512-s2.0-3384653866017270732 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="264" pm="."><plain>23BirgeRBWadsworthSAkakuraRA role for schwann cells in the neuroregenerative effects of a non-immunosuppressive FK506 derivative, JNJ460Neuroscience200412423513662-s2.0-1074422822914980385 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="265" pm="."><plain>24GoldBGDensmoreVShouWMatzukMMGordonHSImmunophilin FK506-binding protein 52 (not FK506-binding protein 12) mediates the neurotrophic action of FK506Journal of Pharmacology and Experimental Therapeutics19992893120212102-s2.0-003303420310336507 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="266" pm="."><plain>25GoldBGVillafrancaJENeuroimmunophilin ligands: the development of novel neuroregenerative/ neuroprotective compoundsCurrent topics in medicinal chemistry2003312136813752-s2.0-014159591212871168 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="267" pm="."><plain>26BarikSImmunophilins: for the love of proteinsCellular and Molecular Life Sciences20066324288929002-s2.0-3384605975517075696 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="268" pm="."><plain>27KarranEMerckenMStrooperBDThe amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeuticsNature Reviews Drug Discovery20111096987122-s2.0-8005226621321852788 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="269" pm="."><plain>28GoldeTEPetrucelliLLewisJTargeting Aβ and tau in Alzheimer’s disease, an early interim reportExperimental Neurology201022322522662-s2.0-7795254975719716367 </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="270" pm="."><plain>29LiaoW-LTsaiF-JPersonalized medicine: a paradigm shift in healthcareBioMedicine2013326672 </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="271" pm="."><plain>30TsaiF-JBiomedicine brings the future nearerBioMedicine2011112-s2.0-80955173849 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="272" pm="."><plain>31TsaiF-JRare diseases: a mysterious puzzleBioMedicine201332, article 65 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="273" pm="."><plain>32ChouICLinW-DWangC-HMöbius syndrome in a male with XX/XY mosaicismBioMedicine201332102104 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="274" pm="."><plain>33LeeC-CTsaiC-HWanLIncreased incidence of Parkinsonism among Chinese with β-glucosidase mutation in central TaiwanBioMedicine2013329294 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="275" pm="."><plain>34LinD-YTsaiF-JTsaiC-HHuangC-YMechanisms governing the protective effect of 17β-estradiol and estrogen receptors against cardiomyocyte injuryBioMedicine20111121282-s2.0-80955174810 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="276" pm="."><plain>35WangC-HLinW-DBauD-TAppearance of acanthosis nigricans may precede obesity: an involvement of the insulin/IGF receptor signaling pathwayBioMedicine2013328287 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="277" pm="."><plain>36ChangY-MVelmuruganBKKuoW-WInhibitory effect of alpinate Oxyphyllae fructus extracts on Ang II-induced cardiac pathological remodeling-related pathways in H9c2 cardiomyoblast cellsBioMedicine201334148152 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="278" pm="."><plain>37ChouICLinW-DWangC-HAssociation analysis between Tourette's syndrome and two dopamine genes (DAT1, DBH) in Taiwanese childrenBioMedicine2013328891 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="279" pm="."><plain>38LinW-YLiuH-PChangJ-SGenetic variations within the PSORS1 region affect Kawasaki disease development and coronary artery aneurysm formationBioMedicine2013327381 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="280" pm="."><plain>39CohenITagliaferriMTripathyDTraditional Chinese medicine in the treatment of breast cancerSeminars in Oncology20022965635742-s2.0-003696968812516039 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="281" pm="."><plain>40LeuenrothSJOkuharaDShotwellJDTriptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney diseaseProceedings of the National Academy of Sciences of the United States of America200710411438943942-s2.0-3424835000417360534 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="282" pm="."><plain>41GongXSucherNJStroke therapy in traditional Chinese medicine (TCM): prospects for drug discovery and developmentPhytomedicine: International Journal of Phytotherapy and Phytopharmacology2002954784842-s2.0-003663696912222672 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="283" pm="."><plain>42La CourBMølgaardPYiZTraditional Chinese medicine in treatment of hyperlipidaemiaJournal of Ethnopharmacology19954621251292-s2.0-00290052767650951 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="284" pm="."><plain>43LiWLZhengHCBukuruJde KimpeNNatural medicines used in the traditional Chinese medical system for therapy of diabetes mellitusJournal of Ethnopharmacology20049211212-s2.0-194242408815099842 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="285" pm="."><plain>44ChangTTSunMFChenHYScreening from the world’s largest TCM database against H1N1 virusJournal of Biomolecular Structure and Dynamics20112857737862-s2.0-7995220919321294588 </plain></SENT>
</text></ref><ref id="B45"><text><SENT sid="286" pm="."><plain>45ChenKCSunMFYangSCInvestigation into Potent Inflammation Inhibitors from Traditional Chinese MedicineChemical Biology and Drug Design20117846796882-s2.0-8005261917421801310 </plain></SENT>
</text></ref><ref id="B46"><text><SENT sid="287" pm="."><plain>46YinJZhangHYeJTraditional Chinese medicine in treatment of metabolic syndromeEndocrine, Metabolic and Immune Disorders—Drug Targets200882991112-s2.0-47249158048 </plain></SENT>
</text></ref><ref id="B47"><text><SENT sid="288" pm="."><plain>47NormileDThe new face of traditional Chinese medicineScience200329956041881902-s2.0-003742819412522228 </plain></SENT>
</text></ref><ref id="B48"><text><SENT sid="289" pm="."><plain>48TsaiTYChangKWChenCYCIScreen: world’s first cloud-computing web server for virtual screening and de novo drug design based on TCM database@TaiwanJournal of Computer-Aided Molecular Design20112565255312-s2.0-8005154569321647737 </plain></SENT>
</text></ref><ref id="B49"><text><SENT sid="290" pm="."><plain>49ChangKWTsaiTYChenKCiSMART: an integrated cloud computing web server for traditional Chinese medicine for online virtual screening, de novo evolution and drug designJournal of Biomolecular Structure and Dynamics20112912432502-s2.0-7995944425121696236 </plain></SENT>
</text></ref><ref id="B50"><text><SENT sid="291" pm="."><plain>50ChenCYChenCYCInsights into designing the dual-targeted HER2/HSP90 inhibitorsJournal of Molecular Graphics and Modelling201029121312-s2.0-7795577255220471294 </plain></SENT>
</text></ref><ref id="B51"><text><SENT sid="292" pm="."><plain>51ChenCYCComputational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5Journal of Molecular Graphics and Modelling20092832612692-s2.0-7034951231319747866 </plain></SENT>
</text></ref><ref id="B52"><text><SENT sid="293" pm="?"><plain>52ChenK-CChenCYCStroke prevention by traditional Chinese medicine? </plain></SENT>
<SENT sid="294" pm="."><plain>A genetic algorithm, support vector machine and molecular dynamics approachSoft Matter201178400140082-s2.0-79953746295 </plain></SENT>
</text></ref><ref id="B53"><text><SENT sid="295" pm="?"><plain>53ChangSSHuangHJChenCYCTwo birds with one stone? </plain></SENT>
<SENT sid="296" pm="."><plain>Possible dual-targeting H1N1 inhibitors from traditional Chinese medicinePLoS Computational Biology20117122-s2.0-84855282742e1002315 </plain></SENT>
</text></ref><ref id="B54"><text><SENT sid="297" pm="."><plain>54YangS-CChangS-SChenH-YChenCY-CIdentification of potent EGFR inhibitors from TCM Database@TaiwanPLoS Computational Biology20117102-s2.0-80055077153e1002189 </plain></SENT>
</text></ref><ref id="B55"><text><SENT sid="298" pm="."><plain>55TouWIChenCYCIn silico investigation of potential Src kinase ligands from traditional chinese medicinePLoS ONE2012732-s2.0-84858674458e33728 </plain></SENT>
</text></ref><ref id="B56"><text><SENT sid="299" pm="."><plain>56TouWIChangSSLeeCCChenCYCDrug design for neuropathic pain regulation from traditional Chinese MedicineScientific Reports20133844 pages23378894 </plain></SENT>
</text></ref><ref id="B57"><text><SENT sid="300" pm="."><plain>57ChenCYCA novel integrated framework and omproved methodology of computer-aided drug designCurrent Topics in Medicinal Chemistry201313996598823651478 </plain></SENT>
</text></ref><ref id="B58"><text><SENT sid="301" pm="."><plain>58ChenCYCTouWLHow to design a drug for the disordered proteinsDrug Discovery Today20131819-2091091523643489 </plain></SENT>
</text></ref><ref id="B59"><text><SENT sid="302" pm="."><plain>59TouWIChenCYMay disordered protein cause serious drug side effect?Drug Discovery Today201419436737224184432 </plain></SENT>
</text></ref><ref id="B60"><text><SENT sid="303" pm="."><plain>60WuBLiPLiuY3D structure of human FK506-binding protein 52: implication for the assembly of the glucocorticoid receptor/Hsp90/immunophilin heterocomplexProceedings of the National Academy of Sciences of the United States of America200410122834883532-s2.0-294259389915159550 </plain></SENT>
</text></ref><ref id="B61"><text><SENT sid="304" pm="."><plain>61GopalakrishnanRKozanyCWangYSExploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52Journal of Medicinal Chemistry20125594123413122455398 </plain></SENT>
</text></ref><ref id="B62"><text><SENT sid="305" pm="."><plain>62ChenCYCTCM database@Taiwan: the world’s largest traditional Chinese medicine database for drug screening in silicoPLoS ONE2011612-s2.0-79251561193e15939 </plain></SENT>
</text></ref><ref id="B63"><text><SENT sid="306" pm="."><plain>63YuJSmithVAWangPPHarteminkAJJarvisEDAdvances to Bayesian network inference for generating causal networks from observational biological dataBioinformatics20042018359436032-s2.0-1234425960215284094 </plain></SENT>
</text></ref><ref id="B64"><text><SENT sid="307" pm="."><plain>64ZoeteVCuendetMAGrosdidierAMichielinOSwissParam: a fast force field generation tool for small organic moleculesJournal of Computational Chemistry20113211235923682-s2.0-7995884170321541964 </plain></SENT>
</text></ref><ref id="B65"><text><SENT sid="308" pm="."><plain>65DardenTAPedersenLGMolecular modeling: an experimental toolEnvironmental Health Perspectives199310154104122-s2.0-00273592418119250 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="FIG"><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="309" pm="."><plain>Correlation plot of observed bioactivity versus predicted bioactivities generated by different models: (a) SVM, (b) MLR, and (c) Bayesian Network. </plain></SENT>
<SENT sid="310" pm="."><plain>Training and test sets are represented by blue circles and red triangles, respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.001"/></fig></SecTag><SecTag type="FIG"><fig id="fig2" orientation="portrait" position="float"><label>Figure 2</label><caption><p><text><SENT sid="311" pm="."><plain>Hydrophobic interactions and H-bonds illustrated through LigPlot for (a) Tacrolimus, (b) Daphnetoxin, (c) 20-O-(2′E,4′E-decadienoyl)ingenol, and (d) Lythrancine II. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.002"/></fig></SecTag><SecTag type="FIG"><fig id="fig3" orientation="portrait" position="float"><label>Figure 3</label><caption><p><text><SENT sid="312" pm="."><plain>Chemical scaffold of (a) Tacrolimus, (b) Daphnetoxin, (c) 20-O-(2′E,4′E-decadienoyl)ingenol, and (d) Lythrancine II. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.003"/></fig></SecTag><SecTag type="FIG"><fig id="fig4" orientation="portrait" position="float"><label>Figure 4</label><caption><p><text><SENT sid="313" pm="."><plain>MD trajectories for (a) protein-ligand complex RMSD, (b) ligand RMSD, and (c) total energy. </plain></SENT>
<SENT sid="314" pm="."><plain>Trajectories for Tacrolimus, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II are shown in pink, mint, blue, and violet, respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.004"/></fig></SecTag><SecTag type="FIG"><fig id="fig5" orientation="portrait" position="float"><label>Figure 5</label><caption><p><text><SENT sid="315" pm="."><plain>Analysis of RMS Fluctuation (RMSF) trajectories generated by Gromacs. </plain></SENT>
<SENT sid="316" pm="."><plain>Trajectories for Tacrolimus, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II are shown in pink, mint, blue, and violet, respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.005"/></fig></SecTag><SecTag type="FIG"><fig id="fig6" orientation="portrait" position="float"><label>Figure 6</label><caption><p><text><SENT sid="317" pm="."><plain>Distance of hydrogen bonds (Å) between FKBP52 and control and TCM candidates versus MD simulation time. </plain></SENT>
<SENT sid="318" pm="."><plain>(a) Tacrolimus, (b) Daphnetoxin, (c) 20-O-(2′E,4′E-decadienoyl)ingenol, and (d) Lythrancine II. </plain></SENT>
<SENT sid="319" pm="."><plain>Horizontal axis represents MD simulation time (ns), and vertical axis represents distance of hydrogen bonds (Å). </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.006"/></fig></SecTag><SecTag type="FIG"><fig id="fig7" orientation="portrait" position="float"><label>Figure 7</label><caption><p><text><SENT sid="320" pm="."><plain>Torsion angles of control and TCM candidates in FKBP52 complex. </plain></SENT>
<SENT sid="321" pm="."><plain>(a) Tacrolimus, (b) Daphnetoxin, (c) 20-O-(2′E,4′E-decadienoyl)ingenol, and (d) Lythrancine II. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.007"/></fig></SecTag><SecTag type="FIG"><fig id="fig8" orientation="portrait" position="float"><label>Figure 8</label><caption><p><text><SENT sid="322" pm="."><plain>Secondary structure changes observed during the 20 ns MD simulation for (a) Tacrolimus, (b) Daphnetoxin, (c) 20-O-(2′E,4′E-decadienoyl)ingenol, and (d) Lythrancine II. </plain></SENT>
<SENT sid="323" pm="."><plain>Their percentages of α-helix, β-sheet, turn, and others are shown in (e), (f), (g), and (h), respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.008"/></fig></SecTag><SecTag type="FIG"><fig id="fig9" orientation="portrait" position="float"><label>Figure 9</label><caption><p><text><SENT sid="324" pm="."><plain>Analysis of MD trajectories generated by Gromacs: (a) solvent accessible surface area of protein, (b) solvent accessible surface area of ligands, (c) radius of gyration of protein, (d) and radius of gyration of ligands. </plain></SENT>
<SENT sid="325" pm="."><plain>Trajectories for Tacrolimus, Daphnetoxin, 20-O-(2′E,4′E-decadienoyl)ingenol, and Lythrancine II are shown in pink, mint, blue, and violet, respectively. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.009"/></fig></SecTag><SecTag type="FIG"><fig id="fig10" orientation="portrait" position="float"><label>Figure 10</label><caption><p><text><SENT sid="326" pm="."><plain>Cluster index and RMSD between amino acid: (a) Tacrolimus, (b) Daphnetoxin, (c) 20-O-(2′E,4′E-decadienoyl)ingenol, and (d) Lythrancine II. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.010"/></fig></SecTag><SecTag type="FIG"><fig id="fig11" orientation="portrait" position="float"><label>Figure 11</label><caption><p><text><SENT sid="327" pm="."><plain>The conformation of protein-ligand complex at 0 ns of MD simulation on the left side compared to the conformation at specific time of MD simulation on the right side. </plain></SENT>
<SENT sid="328" pm="."><plain>The conformations of (a) Tacrolimus, (b) Daphnetoxin, (c) 20-O-(2′E,4′E-decadienoyl)ingenol, and (d) Lythrancine II are at 19.02 ns, 19.32 ns, 19.58 ns, and 19.72 ns during MD simulation, respectively. </plain></SENT>
<SENT sid="329" pm="."><plain>The protein structure and residues shown in blue and the ligand shown in light green indicate the conformation at 0 ns. </plain></SENT>
<SENT sid="330" pm="."><plain>On the other hand, the protein structure and residues shown in violet and the ligand shown in deep green indicate the conformation at specific time of MD simulation. </plain></SENT>
</text></p></caption><graphic xlink:href="ECAM2014-364819.011"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p><text><SENT sid="331" pm="."><plain>Docking scores, bioactivity predictions, and consensus votinga of the TCM candidates and control. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="332" pm="."><plain>Name </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="333" pm="."><plain>SVM </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="334" pm="."><plain>MLR </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="335" pm="."><plain>Bayesian Network </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="336" pm="."><plain>Dock score </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="337" pm="."><plain>Sum of scores </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="338" pm="."><plain>Lathyranoic acid A </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="339" pm="."><plain>4.81 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="340" pm="."><plain>5.12 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="341" pm="."><plain>5.45 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="342" pm="."><plain>86.20 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="343" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="344" pm="."><plain>Daphnetoxin </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="345" pm="."><plain>5.09 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="346" pm="."><plain>8.89 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="347" pm="."><plain>7.46 (2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="348" pm="."><plain>84.88 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="349" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="350" pm="."><plain>Aurantiamide </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="351" pm="."><plain>4.89 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="352" pm="."><plain>6.42 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="353" pm="."><plain>5.43 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="354" pm="."><plain>83.89 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="355" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="356" pm="."><plain>(6aR,11aR)-9,10-Dimethoxypterocarpan-3-O-beta-D-glucoside </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="357" pm="."><plain>5.00 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="358" pm="."><plain>8.33 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="359" pm="."><plain>5.56 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="360" pm="."><plain>83.50 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="361" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="362" pm="."><plain>Picrasidine M </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="363" pm="."><plain>5.10 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="364" pm="."><plain>7.51 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="365" pm="."><plain>5.65 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="366" pm="."><plain>69.60 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="367" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="368" pm="."><plain>12-O-Acetylphorbol-13-tigliate </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="369" pm="."><plain>4.91 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="370" pm="."><plain>7.40 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="371" pm="."><plain>6.15 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="372" pm="."><plain>68.88 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="373" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="374" pm="."><plain>20-O-(2′E,4′E-Decadienoyl)ingenol </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="375" pm="."><plain>4.91 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="376" pm="."><plain>6.87 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="377" pm="."><plain>6.35 (2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="378" pm="."><plain>68.52 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="379" pm="."><plain>2 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="380" pm="."><plain>Howiinol A II </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="381" pm="."><plain>5.24 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="382" pm="."><plain>6.87 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="383" pm="."><plain>5.40 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="384" pm="."><plain>68.11 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="385" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="386" pm="."><plain>Moellendorffiline </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="387" pm="."><plain>5.15 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="388" pm="."><plain>6.64 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="389" pm="."><plain>5.98 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="390" pm="."><plain>63.24 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="391" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="392" pm="."><plain>Lythrancine II </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="393" pm="."><plain>5.03 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="394" pm="."><plain>8.92 (1) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="395" pm="."><plain>6.74 (2) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="396" pm="."><plain>62.03 (0) </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="397" pm="."><plain>3 </plain></SENT>
</text></td></tr><tr><td align="left" colspan="6" rowspan="1"><text><SENT sid="398" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="399" pm="."><plain>Tacrolimus* </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="400" pm="."><plain>5.11  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="401" pm="."><plain>6.25  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="402" pm="."><plain>5.33  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="403" pm="."><plain>58.10  </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="404" pm="."><plain>— </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>*Control. Consensus voting not applied to control.</p></fn><fn><p>
<sup>
a</sup>Voting scores are given in parenthesis.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab2" orientation="portrait" position="float"><label>Table 2</label><caption><p><text><SENT sid="405" pm="."><plain>Protein-ligand interactions recorded during docking. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="406" pm="."><plain>  </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="407" pm="."><plain>Tyr57 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="408" pm="."><plain>Asp68 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="409" pm="."><plain>Arg73 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="410" pm="."><plain>Phe77 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="411" pm="."><plain>Glu85 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="412" pm="."><plain>Val86 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="413" pm="."><plain>Trp90 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="414" pm="."><plain>Tyr113 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="415" pm="."><plain>Lys121 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="416" pm="."><plain>Phe130 </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="417" pm="."><plain>Totala </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="418" pm="."><plain>Tacrolimus </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="419" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="420" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="421" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="422" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="423" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="424" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="425" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="426" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="427" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="428" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="429" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="430" pm="."><plain>Daphnetoxin </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="431" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="432" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="433" pm="."><plain>Pi </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="434" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="435" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="436" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="437" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="438" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="439" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="440" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="441" pm="."><plain>5 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="442" pm="."><plain>20-O-(2′E,4′E-Decadienoyl)ingenol </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="443" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="444" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="445" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="446" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="447" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="448" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="449" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="450" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="451" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="452" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="453" pm="."><plain>7 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="454" pm="."><plain>Lythrancine II </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="455" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="456" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="457" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="458" pm="."><plain>Pi/Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="459" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="460" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="461" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="462" pm="."><plain>H </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="463" pm="."><plain>— </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="464" pm="."><plain>Hb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="465" pm="."><plain>7 </plain></SENT>
</text></td></tr><tr><td align="left" colspan="12" rowspan="1"><text><SENT sid="466" pm="."><plain> </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="467" pm="."><plain>Interaction percentageb </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="468" pm="."><plain>25% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="469" pm="."><plain>75% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="470" pm="."><plain>100% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="471" pm="."><plain>100% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="472" pm="."><plain>25% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="473" pm="."><plain>25% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="474" pm="."><plain>25% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="475" pm="."><plain>100% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="476" pm="."><plain>50% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="477" pm="."><plain>25% </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="478" pm="."><plain>  </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p>
<sup>a</sup>Sum of FKBP52 residues interacting with the specified ligand.</p></fn><fn><p>
<sup>
b</sup>Percentage of ligands which interacts with the specified residue.</p></fn><fn><p>Hb: hydrophobic interaction.</p></fn><fn><p>H: hydrogen bond.</p></fn><fn><p>Pi: <italic>π</italic>-<italic>π</italic> interaction.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="tab3" orientation="portrait" position="float"><label>Table 3</label><caption><p><text><SENT sid="479" pm="."><plain>Radius of gyration (Rg) calculated for the control and TCM candidates. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="480" pm="."><plain>  </plain></SENT>
</text></th><th align="center" colspan="8" rowspan="1"><text><SENT sid="481" pm="."><plain>Radius of gyration (Rg; nm) </plain></SENT>
</text></th></tr><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="482" pm="."><plain>  </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="483" pm="."><plain>Tacrolimus </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="484" pm="."><plain>Daphnetoxin </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="485" pm="."><plain>20-O-(2′E,4′E-Decadienoyl)ingenol </plain></SENT>
</text></th><th align="center" colspan="2" rowspan="1"><text><SENT sid="486" pm="."><plain>Lythrancine II </plain></SENT>
</text></th></tr><tr><th align="left" rowspan="1" colspan="1"><text><SENT sid="487" pm="."><plain>  </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="488" pm="."><plain>Average </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="489" pm="."><plain>Maximum </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="490" pm="."><plain>Average </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="491" pm="."><plain>Maximum </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="492" pm="."><plain>Average </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="493" pm="."><plain>Maximum </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="494" pm="."><plain>Average </plain></SENT>
</text></th><th align="center" rowspan="1" colspan="1"><text><SENT sid="495" pm="."><plain>Maximum </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="496" pm="."><plain>Protein </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="497" pm="."><plain>2.154 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="498" pm="."><plain>2.210 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="499" pm="."><plain>2.179 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="500" pm="."><plain>2.219 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="501" pm="."><plain>2.178 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="502" pm="."><plain>2.237 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="503" pm="."><plain>2.157 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="504" pm="."><plain>2.200 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="505" pm="."><plain>Mainchain </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="506" pm="."><plain>2.140 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="507" pm="."><plain>2.202 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="508" pm="."><plain>2.162 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="509" pm="."><plain>2.205 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="510" pm="."><plain>2.165 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="511" pm="."><plain>2.226 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="512" pm="."><plain>2.142 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="513" pm="."><plain>2.187 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="514" pm="."><plain>Sidechain </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="515" pm="."><plain>2.167 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="516" pm="."><plain>2.216 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="517" pm="."><plain>2.160 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="518" pm="."><plain>2.202 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="519" pm="."><plain>2.190 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="520" pm="."><plain>2.247 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="521" pm="."><plain>2.170 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="522" pm="."><plain>2.212 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="523" pm="."><plain>Backbone </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="524" pm="."><plain>2.137 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="525" pm="."><plain>2.200 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="526" pm="."><plain>2.160 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="527" pm="."><plain>2.202 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="528" pm="."><plain>2.163 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="529" pm="."><plain>2.223 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="530" pm="."><plain>2.140 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="531" pm="."><plain>2.185 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="532" pm="."><plain>C alpha </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="533" pm="."><plain>2.141 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="534" pm="."><plain>2.204 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="535" pm="."><plain>2.165 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="536" pm="."><plain>2.207 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="537" pm="."><plain>2.167 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="538" pm="."><plain>2.227 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="539" pm="."><plain>2.144 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="540" pm="."><plain>2.189 </plain></SENT>
</text></td></tr><tr><td align="left" rowspan="1" colspan="1"><text><SENT sid="541" pm="."><plain>Ligand </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="542" pm="."><plain>0.541 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="543" pm="."><plain>0.575 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="544" pm="."><plain>0.378 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="545" pm="."><plain>0.384 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="546" pm="."><plain>0.570 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="547" pm="."><plain>0.558 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="548" pm="."><plain>0.394 </plain></SENT>
</text></td><td align="center" rowspan="1" colspan="1"><text><SENT sid="549" pm="."><plain>0.413 </plain></SENT>
</text></td></tr></tbody></table></table-wrap></SecTag></floats-group></article>
